Sign In

Login

Password

Forgot Password ? Sign Up

Bilastine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bilastine" in English language version.

refsWebsite
Global rank English rank
16doi.org
2nd place
2nd place
16nih.gov
4th place
4th place
14semanticscholar.org
11th place
8th place
6web.archive.org
1st place
1st place
3tga.gov.au
3,984th place
2,622nd place
1canada.ca
1,712th place
1,063rd place
1medicines.org.uk
3,823rd place
2,387th place
1drugs.com
399th place
333rd place
1mimsonline.com.au
low place
low place

canada.ca

doi.org

drugs.com

medicines.org.uk

mimsonline.com.au

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A (2005). "Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity". Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135.
  • Jáuregui I, Bartra J, del Cuvillo A, Dávila I, Ferrer M, Montoro J, et al. (2011). "Bilastine and quality of life". Journal of Investigational Allergology & Clinical Immunology. 21 (Suppl 3): 16–23. PMID 22185046.
  • Bousquet J, Ansótegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, et al. (January 2012). "Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review". Current Medical Research and Opinion. 28 (1): 131–139. doi:10.1185/03007995.2011.648263. PMID 22149770. S2CID 8429174.
  • Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, et al. (Bilastine International Working Group) (January 2009). "Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients". Allergy. 64 (1): 158–165. doi:10.1111/j.1398-9995.2008.01813.x. PMID 19132976. S2CID 20109223.
  • Church MK, Labeaga L (September 2017). "Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria". Journal of the European Academy of Dermatology and Venereology. 31 (9): 1447–1452. doi:10.1111/jdv.14305. PMID 28467671. S2CID 35712759.
  • Horak F, Zieglmayer P, Zieglmayer R, Lemell P (May 2010). "The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber". Inflammation Research. 59 (5): 391–398. doi:10.1007/s00011-009-0117-4. PMID 19943178. S2CID 30289994.
  • Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, et al. (Bilastine International Working Group) (September 2009). "Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study". Clinical and Experimental Allergy. 39 (9): 1338–1347. doi:10.1111/j.1365-2222.2009.03257.x. PMID 19438584. S2CID 42461412.
  • Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, et al. (April 2010). "Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study". Allergy. 65 (4): 516–528. doi:10.1111/j.1398-9995.2009.02217.x. PMID 19860762. S2CID 24312427.
  • Tyl B, Kabbaj M, Azzam S, Sologuren A, Valiente R, Reinbolt E, et al. (June 2012). "Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis". Journal of Clinical Pharmacology. 52 (6): 893–903. doi:10.1177/0091270011407191. PMID 21642470. S2CID 11649589.
  • Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B (May 2012). "Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study". Clinical Drug Investigation. 32 (5): 339–351. doi:10.2165/11599270-000000000-00000. PMID 22393898. S2CID 22766684.
  • Bailey DG (November 2010). "Fruit juice inhibition of uptake transport: a new type of food-drug interaction". British Journal of Clinical Pharmacology. 70 (5): 645–655. doi:10.1111/j.1365-2125.2010.03722.x. PMC 2997304. PMID 21039758.
  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A (2005). "Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity". Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135.
  • Jáuregui I, García-Lirio E, Soriano AM, Gamboa PM, Antépara I (January 2012). "An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria". Expert Review of Clinical Immunology. 8 (1): 33–41. doi:10.1586/eci.11.87. PMID 22149338. S2CID 207209051.
  • Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M (1 August 2009). "Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine". Clinical Pharmacokinetics. 48 (8): 543–554. doi:10.2165/11317180-000000000-00000. PMID 19705924. S2CID 552051.
  • Montoro J, Mullol J, Dávila I, Ferrer M, Sastre J, Bartra J, et al. (2011). "Bilastine and the central nervous system". Journal of Investigational Allergology & Clinical Immunology. 21 (Suppl 3): 9–15. PMID 22185045.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A (2005). "Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity". Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135.
  • Bousquet J, Ansótegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, et al. (January 2012). "Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review". Current Medical Research and Opinion. 28 (1): 131–139. doi:10.1185/03007995.2011.648263. PMID 22149770. S2CID 8429174.
  • Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, et al. (Bilastine International Working Group) (January 2009). "Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients". Allergy. 64 (1): 158–165. doi:10.1111/j.1398-9995.2008.01813.x. PMID 19132976. S2CID 20109223.
  • Church MK, Labeaga L (September 2017). "Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria". Journal of the European Academy of Dermatology and Venereology. 31 (9): 1447–1452. doi:10.1111/jdv.14305. PMID 28467671. S2CID 35712759.
  • Horak F, Zieglmayer P, Zieglmayer R, Lemell P (May 2010). "The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber". Inflammation Research. 59 (5): 391–398. doi:10.1007/s00011-009-0117-4. PMID 19943178. S2CID 30289994.
  • Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, et al. (Bilastine International Working Group) (September 2009). "Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study". Clinical and Experimental Allergy. 39 (9): 1338–1347. doi:10.1111/j.1365-2222.2009.03257.x. PMID 19438584. S2CID 42461412.
  • Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, et al. (April 2010). "Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study". Allergy. 65 (4): 516–528. doi:10.1111/j.1398-9995.2009.02217.x. PMID 19860762. S2CID 24312427.
  • Tyl B, Kabbaj M, Azzam S, Sologuren A, Valiente R, Reinbolt E, et al. (June 2012). "Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis". Journal of Clinical Pharmacology. 52 (6): 893–903. doi:10.1177/0091270011407191. PMID 21642470. S2CID 11649589.
  • Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B (May 2012). "Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study". Clinical Drug Investigation. 32 (5): 339–351. doi:10.2165/11599270-000000000-00000. PMID 22393898. S2CID 22766684.
  • Bachert C, Kuna P, Zuberbier T (1 June 2010). "Bilastine in allergic rhinoconjunctivitis and urticaria". Allergy. 65: 1–13. doi:10.1111/j.1398-9995.2010.02404.x. S2CID 52228628.
  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A (2005). "Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity". Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135.
  • Jáuregui I, García-Lirio E, Soriano AM, Gamboa PM, Antépara I (January 2012). "An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria". Expert Review of Clinical Immunology. 8 (1): 33–41. doi:10.1586/eci.11.87. PMID 22149338. S2CID 207209051.
  • Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M (1 August 2009). "Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine". Clinical Pharmacokinetics. 48 (8): 543–554. doi:10.2165/11317180-000000000-00000. PMID 19705924. S2CID 552051.
  • Church MK (2021). "Antihistamines". Urticaria and Angioedema. Springer International Publishing. pp. 153–165. doi:10.1007/978-3-030-84574-2_11. ISBN 978-3-030-84573-5. S2CID 239944965.

tga.gov.au

ebs.tga.gov.au

  • "Australian Product Information - Allertine (Bilastine) tablet". Therapeutic Goods Administration. 27 April 2022. Archived from the original on 13 September 2022. Retrieved 13 September 2022.
  • "Public summary - ALLERTINE bilastine 20 mg tablet blister pack". Therapeutic Goods Administration. 27 April 2022. Archived from the original on 7 December 2022. Retrieved 13 September 2022.

tga.gov.au

web.archive.org

  • "Australian Product Information - Allertine (Bilastine) tablet". Therapeutic Goods Administration. 27 April 2022. Archived from the original on 13 September 2022. Retrieved 13 September 2022.
  • "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
  • "Public summary - ALLERTINE bilastine 20 mg tablet blister pack". Therapeutic Goods Administration. 27 April 2022. Archived from the original on 7 December 2022. Retrieved 13 September 2022.
  • "Ilaxten 20 mg tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 24 June 2021. Retrieved 16 June 2021.
  • Bilastine Approval Status Archived 2023-08-27 at the Wayback Machine, drugs.com
  • "Allertine (bilastine)". MIMS. Archived from the original on 28 November 2023. Retrieved 13 September 2022.